sur B.R.A.I.N. Biotechnology Research And Information Network AG (ETR:DE000520)
BRAIN Biotech AG Shows Resilience Amid Economic Challenges in FY 2024/25
BRAIN Biotech AG, renowned for its specialized enzymes and biosolutions, published its financial results for FY 2024/25, indicating a challenging sales environment. The company faced a fall in revenue, down from €54.6 million to €49.6 million, mainly due to external factors impacting pharma-related services. Despite this, strong cost control measures helped maintain a stable adjusted EBITDA and a solid cash position of €6.2 million.
CEO Adriaan Moelker highlighted the mixed outcomes of the year, noting success in monetizing projects from the BRAINBioIncubator pipeline as a strategic gain. Revenue from BRAINBioIncubator fell significantly, impacted by a lack of repeated milestone income in the pharma sector. Nonetheless, strategic measures, including a CRISPR-Cas technology spin-out, resulted in improved EBITDA.
The outlook for 2025/26 anticipates slight revenue growth and improved performance in the BRAINBioIncubator segment with adjustments in operations and strategy set to bolster future growth.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de B.R.A.I.N. Biotechnology Research And Information Network AG